Hepatitis Monthly

Published by: Kowsar

Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma

Shawky Abdelhamid Fouad 1 , * , Nagwa Abdel Ghaffar Mohamed 2 , Mary Wadie Fawzy 1 and Doaa Ali Moustafa 1
Authors Information
1 Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of Clinical and Chemical Pathology, National Research Center, Giza, Egypt
Article information
  • Hepatitis Monthly: September 01, 2015, 15 (9); e30753
  • Published Online: September 1, 2015
  • Article Type: Research Article
  • Received: June 14, 2015
  • Revised: July 31, 2015
  • Accepted: August 16, 2015
  • DOI: 10.5812/hepatmon.30753

To Cite: Fouad S A, Mohamed N A G, Fawzy M W, Moustafa D A. Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma, Hepat Mon. 2015 ; 15(9):e30753. doi: 10.5812/hepatmon.30753.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 2014; 44(1): 22-30[DOI][PubMed]
  • 2. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000; 287(5454): 860-4[PubMed]
  • 3. Suzuki H, Amizuka N, Oda K, Li M, Yoshie H, Ohshima H, et al. Histological evidence of the altered distribution of osteocytes and bone matrix synthesis in klotho-deficient mice. Arch Histol Cytol. 2005; 68(5): 371-81[PubMed]
  • 4. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7(15): 1475-82[PubMed]
  • 5. Huang W, Zhu G, Huang M, Lou G, Liu Y, Wang S. Plasma osteopontin concentration correlates with the severity of hepatic fibrosis and inflammation in HCV-infected subjects. Clin Chim Acta. 2010; 411(9-10): 675-8[DOI][PubMed]
  • 6. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007; 56(6): 782-9[DOI][PubMed]
  • 7. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011; 53(1): 106-15[DOI][PubMed]
  • 8. Ranjbar Kermani F, Sharifi Z, Ferdowsian F, Paz Z, Tavassoli F. The Usefulness of Anti-HCV Signal to Cut-off Ratio in Predicting Viremia in Anti-HCV in Patients With Hepatitis C Virus Infection. Jundishapur J Microbiol. 2015; 8(4)
  • 9. Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, et al. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon. 2013; 13(6)[DOI][PubMed]
  • 10. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94(2): 153-6[PubMed]
  • 11. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant. 2001; 1(3): 197-203[PubMed]
  • 12. El-Zanaty F, Wany A. Egypt Demographic and Health Survey 2008. 2009;
  • 13. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2): 107-15[DOI][PubMed]
  • 14. Bruix J, Sherman M, Practice Guidelines Committee AAFTSOLD. Management of hepatocellular carcinoma. Hepatology. 2005; 42(5): 1208-36[DOI][PubMed]
  • 15. Ostheimer C, Bache M, Guttler A, Reese T, Vordermark D. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014; 14: 858[DOI][PubMed]
  • 16. Fouad SA, Elsaaid NH, Mohamed NA, Abutaleb OM. Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIalpha in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma. Hepat Mon. 2014; 14(9)[DOI][PubMed]
  • 17. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366(3): 216-24[DOI][PubMed]
  • 18. Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol . 2006; 101(8): 1939
  • 19. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012; 55(2): 483-90[DOI][PubMed]
  • 20. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res. 2004; 29(4): 202-6[DOI][PubMed]
  • 21. Wang JH, Changchien CS, Hu TH, Lee CM, Kee KM, Lin CY, et al. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma - Survival analysis of 3892 patients. Eur J Cancer. 2008; 44(7): 1000-6[DOI][PubMed]
  • 22. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006; 101(9): 2051-9[DOI][PubMed]
  • 23. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008; 103(1): 4-13[DOI][PubMed]
  • 24. Taketa K, Okada S, Win N, Hlaing NK, Wind KM. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama. 2002; 56(6): 317-20[PubMed]
  • 25. Gad A, Tanaka E, Matsumoto A, El-Hamid Serwah A, Attia F, Hassan A, et al. Ethnicity affects the diagnostic validity of alpha-fetoprotein in hepatocellular carcinoma. Asia-Pacific J Clin Oncol. 2005; 1(2-3): 64-70[DOI]
  • 26. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008; 62(7): 1056-62[DOI][PubMed]
  • 27. Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2012; 130(11): 2685-92[DOI][PubMed]
  • 28. Yilmaz Y, Ozturk O, Alahdab YO, Senates E, Colak Y, Doganay HL, et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2013; 45(1): 58-62[DOI][PubMed]
  • 29. El-Din Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH. Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res. 2010; 41(7): 541-7[DOI][PubMed]
  • 30. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, et al. Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol. 2011; 10(3): 296-305[PubMed]
  • 31. Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab J Gastroenterol. 2014; 15(3-4): 103-7[DOI][PubMed]
  • 32. Keddeas MW, Abo-shady RA. Evaluation of plasma osteopontin level as a biomarker for hepatocellular carcinoma in Egyptian patients. Egypt Liver J. 2011; 1(1): 38-42[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments